Breaking News Instant updates and real-time market news.

MDGL

Madrigal Pharmaceuticals

$200.68

-4.42 (-2.16%)

06:52
11/06/18
11/06
06:52
11/06/18
06:52

Madrigal Pharmaceuticals reports Q3 EPS (56c), consensus (53c)

  • 12

    Nov

  • 20

    Nov

MDGL Madrigal Pharmaceuticals
$200.68

-4.42 (-2.16%)

09/18/18
HCWC
09/18/18
NO CHANGE
Target $28
HCWC
Buy
H.C. Wainwright boosts Viking Therapeutics target to $28 on 'mic drop' data
H.C. Wainwright analyst Joseph Pantginis raised his price target for Viking Therapeutics (VKTX) to $28 from $15 saying this morning's VK2809 top-line data in nonalcoholic fatty liver disease and elevated LDL-cholesterol "hit their endpoints in a significant fashion." The stock in midday trading is up 78%, or $8.11, to $18.50. Further, the drug's 12-week safety profile has represents a hit to the bear thesis on the shares, Pantginis tells investors in an intraday research note titled "Tuesday Morning Mic Drop as VK2809 Serves Notice; Target Increased to $28." VK2809 treated patients showed an encouraging overall safety profile, which may further prove the superiority of Viking's VK2809 versus its peers in the nonalcoholic fatty liver disease arena, the analyst adds. He believes Viking's data could be superior to Madrigal Pharmaceuticals' (MDGL). Pantginis reiterates a Buy rating on Viking Therapeutics.
09/18/18
RAJA
09/18/18
NO CHANGE
RAJA
Outperform
Viking NAFLD data beat 'optimistic expectations,' says Raymond James
Raymond James analyst Steven Seedhouse said the Phase 2 study data reported by Viking Therapeutics (VKTX) for VK2809 in patients with elevated LDL-C and NAFLD beat even his "optimistic expectations" and that its effect on MRI-PDFF, the key Phase 2 surrogate endpoint for predicting NASH biopsy improvement, is "better than every other oral NASH drug in development." Following Viking's report, Seedhouse sees the only advantage retained by Madrigal Pharmaceuticals (MDGL) at this point being its time to Phase 3, he added. Seedhouse maintains an Outperform rating on Viking shares.
09/19/18
HCWC
09/19/18
NO CHANGE
HCWC
H.C. Wainwright points out Viking is years behind Madrigal, Genfit
In interpreting and reacting to Viking Therapeutics' (VKTX) Phase II VK2809 data yesterday, the market has gotten ahead of itself, especially relative to Madrigal Pharmaceuticals (MDGL) and Genfit (GNFTF), H.C. Wainwright analyst Ed Arce tells investors in a research note. The analyst sees "several significant limitations" of the Viking study, including a small sample size that he says limits the reliability of results, the non-alcoholic fatty liver disease patient population, which he notes is not the same as nonalcoholic steatohepatitis, its LDL reductions being similar to other agents, and the analyst's belief that safety questions remain. Further, he reminds investors that Viking is still, "at best," three-to-four years behind Genfit and Madrigal. The VK2809 efficacy data look strong, but evaluating it by other compounds is comparing apples to oranges, Arce contends. The analyst continues to believe that Genfit's market valuation is "substantially below" its intrinsic value.
09/26/18
JMPS
09/26/18
NO CHANGE
Target $300
JMPS
Outperform
JMP Securities 'optimistic' on Madrigal following Amarin's Vascepa data
JMP Securities analyst Liisa Bayko said she feels "optimistic" regarding MGL-3196's potential cardiovascular benefit following Amarin's (AMRN) announcement that Vascepa reduced the risk of major adverse CV events in the REDUCE-IT long-term outcomes study. The REDUCE-IT data lays an argument that Madrigal's MGL-3196, which has a similar impact on cardiometabolic parameters, may also provide a CV benefit, contends Bayko. She maintains an Outperform rating and $300 price target on Madrigal Pharmaceuticals shares.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.80

0.96 (0.35%)

13:12
11/16/18
11/16
13:12
11/16/18
13:12
Periodicals
White House says Trump just expressing optimism on trade, CNBC reports »

CNBC's Eamon Javers…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.80

0.96 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.79

0.95 (0.35%)

13:10
11/16/18
11/16
13:10
11/16/18
13:10
Periodicals
White House tells CNBC not to read too much into Trump's trade comments »

Immediately following…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.79

0.95 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:09
11/16/18
11/16
13:09
11/16/18
13:09
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 11/16…

BHGE

Baker Hughes

$23.40

0.11 (0.47%)

13:05
11/16/18
11/16
13:05
11/16/18
13:05
Hot Stocks
Baker Hughes reports U.S. rig count up 1 to 1,082 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 14

    Nov

ECA

Encana

$7.56

-0.19 (-2.45%)

13:05
11/16/18
11/16
13:05
11/16/18
13:05
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$8.03

0.16 (2.03%)

13:00
11/16/18
11/16
13:00
11/16/18
13:00
Recommendations
Syros Pharmaceuticals analyst commentary  »

Syros Phase I dose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$273.77

0.93 (0.34%)

12:54
11/16/18
11/16
12:54
11/16/18
12:54
General news
Trump says China 'wants to make a deal' on trade »

President Trump said in…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$273.77

0.93 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$85.27

-1.48 (-1.71%)

12:50
11/16/18
11/16
12:50
11/16/18
12:50
Options
Notable call writing in Paypal as shares drop 2% »

Notable call writing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 18

    Dec

GOOG

Alphabet

$1,051.92

-12.82 (-1.20%)

, GOOGL

Alphabet Class A

$1,057.14

-14.08 (-1.31%)

12:49
11/16/18
11/16
12:49
11/16/18
12:49
Periodicals
Google Cloud CEO to be replaced by former Oracle executive, CNBC reports »

Google (GOOG, GOOGL)…

GOOG

Alphabet

$1,051.92

-12.82 (-1.20%)

GOOGL

Alphabet Class A

$1,057.14

-14.08 (-1.31%)

ORCL

Oracle

$51.16

0.52 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.08

-0.76 (-0.28%)

12:45
11/16/18
11/16
12:45
11/16/18
12:45
General news
Markets bounce higher after Trump comments on China trade talks »

The markets moved higher…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.08

-0.76 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/16/18
11/16
12:45
11/16/18
12:45
General news
Breaking General news story  »

Week of 11/16…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says would like to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says does not want…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$20.54

-0.53 (-2.52%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
Options
4K Jun 22.5 calls on iQiyi trade $3.40 »

4K Jun 22.5 calls on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$138.09

-5.77 (-4.01%)

12:38
11/16/18
11/16
12:38
11/16/18
12:38
Hot Stocks
Definers says not hired by Facebook for opposition research »

Definers Public Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LYB

LyondellBasell

$94.38

0.95 (1.02%)

, BAK

Braskem

$27.66

0.56 (2.07%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell (LYB) is…

LYB

LyondellBasell

$94.38

0.95 (1.02%)

BAK

Braskem

$27.66

0.56 (2.07%)

PBR

Petrobras

$14.87

0.32 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$68.91

0.24 (0.35%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Options
Call buying in Cognizant Tech as the company hosts an Investor Day Friday »

Call buying in Cognizant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 26

    Nov

  • 02

    Dec

BAK

Braskem

$27.74

0.64 (2.36%)

, LYB

LyondellBasell

$94.44

1.01 (1.08%)

12:26
11/16/18
11/16
12:26
11/16/18
12:26
Hot Stocks
Breaking Hot Stocks news story on Braskem, LyondellBasell »

Braskem up 54c to $27.68…

BAK

Braskem

$27.74

0.64 (2.36%)

LYB

LyondellBasell

$94.44

1.01 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Periodicals
Airbus, Dassault plan to submit bid for early work on new jet, Reuters says »

Airbus and Dassault…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

LYB

LyondellBasell

$94.48

1.05 (1.12%)

12:24
11/16/18
11/16
12:24
11/16/18
12:24
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell is close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$54.66

-0.04 (-0.07%)

12:20
11/16/18
11/16
12:20
11/16/18
12:20
Options
Bearish option flow in Materials Sector ETF »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:20
11/16/18
11/16
12:20
11/16/18
12:20
General news
More from Evans: the short-term policy rate is the first instrument »

More from Evans: the…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/16/18
11/16
12:17
11/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/16/18
11/16
12:16
11/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.